TY - JOUR
T1 - Concomitant congenital CMV infection and inherited liver diseases
AU - Swed-Tobia, Rana
AU - Kassis, Imad
AU - Weiss, Karin
AU - Tal, Galit
AU - Shaoul, Ron
AU - Falik-Zaccai, Tzipora C.
AU - Mandel, Hanna
AU - Meir, Michal
N1 - Publisher Copyright:
© 2021 Elsevier Masson SAS
PY - 2021/8
Y1 - 2021/8
N2 - Inherited liver diseases may present in infancy as cholestatic jaundice progressing to severe hepatic dysfunction. Congenital cytomegalovirus (cCMV) infection may initially involve the liver, yet in otherwise healthy hosts rarely leads to long-term hepatic disease. We report a series of three patients, diagnosed with hereditary liver diseases: progressive familial intrahepatic cholestasis (PFIC) type IV, alpha 1 anti-trypsin deficiency (A1ATD) and Alagille syndrome (ALGS), who were also diagnosed with cCMV infection. All patients were treated with valgancilovir for symptomatic cCMV infection (6–12 months), followed by suppressive dosing in the 2 patients with PFIC and A1ATD. Following 15–24 months of follow-up – the patients with PFIC and A1ATD developed severe liver failure, and the third had ongoing cholestatic disease with stable synthetic function. We propose a significant contribution of cCMV infection to the course of the inherited primary disease, possibly leading to further compromise of the liver. We recommend screening patients with inherited liver disease for cCMV, and considering anti-viral treatment with valganciclovir to delay hepatic disease progression.
AB - Inherited liver diseases may present in infancy as cholestatic jaundice progressing to severe hepatic dysfunction. Congenital cytomegalovirus (cCMV) infection may initially involve the liver, yet in otherwise healthy hosts rarely leads to long-term hepatic disease. We report a series of three patients, diagnosed with hereditary liver diseases: progressive familial intrahepatic cholestasis (PFIC) type IV, alpha 1 anti-trypsin deficiency (A1ATD) and Alagille syndrome (ALGS), who were also diagnosed with cCMV infection. All patients were treated with valgancilovir for symptomatic cCMV infection (6–12 months), followed by suppressive dosing in the 2 patients with PFIC and A1ATD. Following 15–24 months of follow-up – the patients with PFIC and A1ATD developed severe liver failure, and the third had ongoing cholestatic disease with stable synthetic function. We propose a significant contribution of cCMV infection to the course of the inherited primary disease, possibly leading to further compromise of the liver. We recommend screening patients with inherited liver disease for cCMV, and considering anti-viral treatment with valganciclovir to delay hepatic disease progression.
KW - Congenital CMV
KW - Inherited liver diseases
KW - Liver dysfunction
KW - Valganciclovir
UR - http://www.scopus.com/inward/record.url?scp=85106590620&partnerID=8YFLogxK
U2 - 10.1016/j.ejmg.2021.104249
DO - 10.1016/j.ejmg.2021.104249
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34023521
AN - SCOPUS:85106590620
SN - 1769-7212
VL - 64
JO - European Journal of Medical Genetics
JF - European Journal of Medical Genetics
IS - 8
M1 - 104249
ER -